Compare KTTA & SDST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KTTA | SDST |
|---|---|---|
| Founded | 2020 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1M | 16.5M |
| IPO Year | 2021 | 2020 |
| Metric | KTTA | SDST |
|---|---|---|
| Price | $0.55 | $0.37 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 216.1K | ★ 1.6M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.07 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $486,559.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3130.37 | N/A |
| 52 Week Low | $0.28 | $0.28 |
| 52 Week High | $2.06 | $7.67 |
| Indicator | KTTA | SDST |
|---|---|---|
| Relative Strength Index (RSI) | 62.85 | 21.87 |
| Support Level | $0.54 | N/A |
| Resistance Level | $0.61 | $0.73 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 92.85 | 4.50 |
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).